

Maria T Voso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5345984/publications.pdf>

Version: 2024-02-01

254
papers

8,518
citations

47006
47
h-index

66911
78
g-index

261
all docs

261
docs citations

261
times ranked

8767
citing authors

#	ARTICLE	IF	CITATIONS
1	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	30.7	372
2	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 972-979.	1.6	296
3	PU.1 (Spi-1) and C/EBP β Regulate Expression of the Granulocyte-Macrophage Colony-Stimulating Factor Receptor β Gene. <i>Molecular and Cellular Biology</i> , 1995, 15, 5830-5845.	2.3	271
4	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
5	Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. <i>Blood</i> , 1995, 85, 2918-2928.	1.4	212
6	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	1.6	204
7	Therapy-related leukemia and myelodysplasia: susceptibility and incidence. <i>Haematologica</i> , 2007, 92, 1389-1398.	3.5	184
8	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	1.4	148
9	Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 7932-7936.	7.1	142
10	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017, 4, e127-e136.	4.6	132
11	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	1.4	127
12	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	1.6	127
13	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2671-2677.	1.6	121
14	Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN γ . <i>European Journal of Immunology</i> , 2004, 34, 1291-1302.	2.9	120
15	Therapy Related Leukemias: Susceptibility, Prevention and Treatment. <i>Leukemia and Lymphoma</i> , 2001, 41, 255-276.	1.3	115
16	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , 2007, 18, 346-350.	1.2	111
17	Function of PU.1 (Spi-1), C/EBP, and AML1 in Early Myelopoiesis: Regulation of Multiple Myeloid CSF Receptor Promoters. <i>Current Topics in Microbiology and Immunology</i> , 1996, 211, 137-147.	1.1	111
18	Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	1.4	110

#	ARTICLE	IF	CITATIONS
19	Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2009, 20, 1408-1413.	1.2	110
20	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	7.0	103
21	Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. <i>Clinical Immunology</i> , 2003, 109, 89-102.	3.2	93
22	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	4.1	93
23	MRD in AML: The Role of New Techniques. <i>Frontiers in Oncology</i> , 2019, 9, 655.	2.8	93
24	Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). <i>European Journal of Haematology</i> , 2014, 92, 527-536.	2.2	90
25	The Viral Load of Epstein-Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2011, 17, 2885-2892.	7.0	89
26	Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin. <i>Journal of Clinical Oncology</i> , 2010, 28, 2538-2543.	1.6	86
27	Incidence and susceptibility to therapy-related myeloid neoplasms. <i>Chemico-Biological Interactions</i> , 2010, 184, 39-45.	4.0	85
28	In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2000, 109, 729-735.	2.5	80
29	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , The, 2008, 9, 352-358.	10.7	80
30	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. <i>Leukemia</i> , 2014, 28, 621-628.	7.2	80
31	Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. <i>Blood</i> , 2004, 103, 698-700.	1.4	79
32	Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2005, 11, 2175-2179.	7.0	77
33	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	10.7	76
34	PML-RAR α kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. <i>Leukemia</i> , 2016, 30, 1987-1992.	7.2	75
35	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. <i>Blood</i> , 2008, 112, 3383-3390.	1.4	74
36	Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. <i>Blood</i> , 1995, 85, 2918-28.	1.4	71

#	ARTICLE	IF	CITATIONS
37	Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies. <i>Cancers</i> , 2019, 11, 1591.	3.7	70
38	Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2006, 95, 1108-1113.	6.4	69
39	Nongastric Marginalâ€Žone Bâ€ŽCell MALT Lymphoma: Prognostic Value of Disease Dissemination. <i>Oncologist</i> , 2006, 11, 285-291.	3.7	63
40	Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. <i>Annals of Oncology</i> , 2007, 18, 1523-1528.	1.2	61
41	Why methylation is not a marker predictive of response to hypomethylating agents. <i>Haematologica</i> , 2014, 99, 613-619.	3.5	61
42	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 658-661.	1.3	54
43	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratificationâ€”an approach to classification of patients with t-MDS. <i>Leukemia</i> , 2021, 35, 835-849.	7.2	54
44	Immunomagnetic selection of CD34 + peripheral blood stem cells for autografting in patients with breast cancer. <i>British Journal of Haematology</i> , 1997, 97, 881-888.	2.5	51
45	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	7.2	51
46	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	7.2	51
47	CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancerâ€”binding protein alpha. <i>Blood</i> , 2007, 110, 3695-3705.	1.4	50
48	Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jka after allogeneic PBPC transplantation. <i>Transfusion</i> , 2000, 40, 632-636.	1.6	49
49	Therapy-related myeloid neoplasms. <i>Current Opinion in Oncology</i> , 2011, 23, 672-680.	2.4	49
50	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44.	17.0	49
51	Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2007, 18, 1376-1381.	1.2	47
52	High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts <i>in vitro</i>. <i>Oncotarget</i> , 2017, 8, 32550-32565.	1.8	47
53	Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). <i>Bone Marrow Transplantation</i> , 2000, 25, 957-964.	2.4	46
54	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017, 28, 1547-1553.	1.2	46

#	ARTICLE	IF	CITATIONS
55	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	7.2	46
56	Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 664-70.	3.5	46
57	Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 2275-2284.	1.3	43
58	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. <i>Leukemia and Lymphoma</i> , 2014, 55, 270-275.	1.3	43
59	Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. <i>Clinical Cancer Research</i> , 2003, 9, 3435-40.	7.0	43
60	Identification of a Novel Subpopulation of Human Cord Blood CD34 ⁺ CD133 ⁺ CD7 ⁺ CD45 ⁺ Lineage ⁻ Cells Capable of Lymphoid/NK Cell Differentiation After In Vitro Exposure to IL-15. <i>Journal of Immunology</i> , 2003, 171, 2977-2988.	0.8	42
61	Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias. <i>Current Medicinal Chemistry</i> , 2008, 15, 1274-1287.	2.4	42
62	Impairment of PI3K/AKT and WNT/ β -catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016, 44, 75-83.e4.	0.4	42
63	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	7.2	42
64	Autografting with CD34 ⁺ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. <i>British Journal of Haematology</i> , 1999, 104, 382-391.	2.5	40
65	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacitidine. <i>Leukemia</i> , 2011, 25, 1910-1913.	7.2	40
66	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. <i>Blood Advances</i> , 2022, 6, 2219-2229.	5.2	40
67	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	3.4	39
68	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014, 25, 447-454.	1.2	38
69	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. <i>Blood</i> , 2022, 139, 2145-2155.	1.4	38
70	Risk of acute promyelocytic leukemia in multiple sclerosis. <i>Neurology</i> , 2011, 76, 1059-1065.	1.1	37
71	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348.	2.2	37
72	Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. <i>Leukemia</i> , 2008, 22, 1685-1691.	7.2	36

#	ARTICLE	IF	CITATIONS
73	Epigenetic changes in therapy-related MDS/AML. <i>Chemico-Biological Interactions</i> , 2010, 184, 46-49.	4.0	36
74	Interleukin-6 plasma levels are modulated by a polymorphism in the <i>NF-κB1</i> gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 411-416.	1.3	36
75	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , 2016, 12, 293-302.	2.4	36
76	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
77	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 785-790.	7.2	33
78	Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: Role of heat-shock protein-70. , 1997, 73, 75-83.		32
79	Fanconi anemia gene variants in therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2015, 5, e323-e323.	6.2	32
80	Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. <i>Leukemia Research</i> , 2009, 33, 1352-1356.	0.8	31
81	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351.	2.2	31
82	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. <i>BMC Hematology</i> , 2016, 16, 12.	2.6	31
83	The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. <i>Haematologica</i> , 2019, 104, 973-985.	3.5	31
84	Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. <i>Annals of Oncology</i> , 2008, 19, 128-134.	1.2	30
85	Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. <i>Scientific Reports</i> , 2021, 11, 12762.	3.3	29
86	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 181-185.	1.4	28
87	Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 331-333.	0.8	28
88	CD 68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. <i>Cancer Medicine</i> , 2016, 5, 398-406.	2.8	28
89	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 285-287.	1.5	27
90	Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma. <i>Blood</i> , 1997, 89, 3763-3768.	1.4	27

#	ARTICLE	IF	CITATIONS
91	Microchimerism in bone marrow‐derived CD34+ cells of patients after liver transplantation. Blood, 2000, 96, 763-767.	1.4	26
92	Azacitidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Leukemia Research, 2015, 39, 801-804.	0.8	25
93	An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. Annals of Hematology, 2015, 94, 771-777.	1.8	25
94	Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leukemia Research, 2017, 62, 108-115.	0.8	25
95	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. American Journal of Hematology, 2019, 94, 1091-1097.	4.1	25
96	Combined Voriconazole Plus Caspofungin Therapy for the Treatment of Probable Geotrichum Pneumonia in a Leukemia Patient. Infection, 2008, 36, 65-67.	4.7	24
97	INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011069.	1.3	24
98	Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia. Neoplasia, 2015, 17, 401-409.	5.3	24
99	Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 628-634.	1.3	24
100	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Advances, 2022, 6, 2207-2218.	5.2	24
101	Polymorphisms of detoxification and DNA repair enzymes in myelodysplastic syndromes. Leukemia Research, 2009, 33, 1068-1071.	0.8	23
102	Mutations affecting both the rearranged and the unrearranged <i><sc>PML</sc></i> alleles in refractory acute promyelocytic leukaemia. British Journal of Haematology, 2016, 172, 909-913.	2.5	23
103	Panobinostat for the treatment of acute myelogenous leukemia. Expert Opinion on Investigational Drugs, 2016, 25, 1117-1131.	4.1	23
104	Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. British Journal of Haematology, 2017, 177, 741-750.	2.5	23
105	What‐s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood, 2021, 138, 749-757.	1.4	23
106	Have we reached a molecular era in myelodysplastic syndromes?. Hematology American Society of Hematology Education Program, 2021, 2021, 418-427.	2.5	23
107	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia, 2013, 27, 982-985.	7.2	22
108	The<i>BCL2L10</i>Leu21Arg variant and risk of therapy-related myeloid neoplasms and<i>de novo</i>myelodysplastic syndromes. Leukemia and Lymphoma, 2014, 55, 1538-1543.	1.3	22

#	ARTICLE	IF	CITATIONS
109	Deferasirox chelation therapy in patients with transfusionâ€dependent <scp>MDS</scp>: a â€realâ€worldâ€™ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. European Journal of Haematology, 2015, 95, 52-56.	2.2	22
110	The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-ÎB activation. Cancer Letters, 2018, 423, 127-138.	7.2	22
111	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. Cancers, 2019, 11, 865.	3.7	22
112	Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. Blood Advances, 2019, 3, 4155-4160.	5.2	22
113	Clonal evolution in therapy-related neoplasms. Oncotarget, 2017, 8, 12031-12040.	1.8	22
114	Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplantation, 2017, 52, 473-475.	2.4	21
115	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. Expert Review of Hematology, 2018, 11, 307-313.	2.2	21
116	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Annals of Hematology, 2018, 97, 1797-1802.	1.8	20
117	The dose of granulocyte colonyâ€stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+haemopoietic progenitor cells during marrow recovery. British Journal of Haematology, 1998, 101, 588-591.	2.5	19
118	Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Current Opinion in Oncology, 2015, 27, 532-539.	2.4	19
119	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochemical Pharmacology, 2019, 167, 133-148.	4.4	19
120	When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. Chemotherapy, 2019, 64, 238-247.	1.6	19
121	Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood, 2021, 138, 1331-1344.	1.4	19
122	PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. Oncotarget, 2016, 7, 66386-66397.	1.8	19
123	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016052.	1.3	18
124	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. Cancers, 2020, 12, 1746.	3.7	18
125	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Leukemia Research, 2015, 39, 859-865.	0.8	17
126	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinicoâ€biological parameters. British Journal of Haematology, 2021, 193, 129-132.	2.5	17

#	ARTICLE	IF	CITATIONS
127	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	12.8	17
128	Prevalence of the 677C to T Mutation in the Methylenetetrahydrofolate Reductase Gene in Italian Patients with Venous Thrombotic Disease. <i>Thrombosis and Haemostasis</i> , 1998, 79, 686-687.	3.4	16
129	PLI.1 and CEBPA expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1448-1453.	0.8	16
130	Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 467-476.	2.8	16
131	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. <i>Haematologica</i> , 2014, 99, e152-e153.	3.5	16
132	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. <i>BMJ Supportive and Palliative Care</i> , 2016, 6, 80-88.	1.6	16
133	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1527-1530.	7.2	16
134	In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. <i>Haematologica</i> , 2004, 89, 634-6.	3.5	16
135	Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis. <i>Frontiers in Oncology</i> , 2022, 12, 871590.	2.8	16
136	Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 474-478.	0.8	15
137	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 1767-1774.	1.8	15
138	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 16-25.	5.7	15
139	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 564-569.	1.3	14
140	Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. <i>Bone Marrow Transplantation</i> , 2010, 45, 1668-1670.	2.4	14
141	Treatment of Philadelphiaa€negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295.	1.7	14
142	Identification and monitoring of atypicalPML/RARafusion transcripts in acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 60-65.	2.8	14
143	Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor. <i>Gene</i> , 1998, 207, 209-218.	2.2	13
144	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. <i>Cancers</i> , 2019, 11, 1373.	3.7	13

#	ARTICLE	IF	CITATIONS
145	Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2006, 4, 33-52.	1.0	12
146	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 805-807.	1.2	12
147	Therapy-related myeloid neoplasms: clinical perspectives. OncoTargets and Therapy, 2018, Volume 11, 5909-5915.	2.0	12
148	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells, 2020, 9, 2423.	4.1	12
149	Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. International Journal of Molecular Sciences, 2021, 22, 642.	4.1	12
150	Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. Cancers, 2022, 14, 2565.	3.7	12
151	Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. Leukemia Research, 2011, 35, 465-471.	0.8	11
152	<scp>PML</scp></scp>RARA</scp> inhibits expression of <scp>HSP</scp>90 and its target <scp>AKT</scp>. British Journal of Haematology, 2019, 184, 937-948.	2.5	11
153	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. Cancers, 2020, 12, 357.	3.7	11
154	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer Journal, 2021, 11, 167.	6.2	11
155	HIGHÊDOSE THERAPY WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION RESULTS IN A SIGNIFICANT REDUCTION OF THE HaEMOPOIETIC PROGENITOR CELL COMPARTMENT. British Journal of Haematology, 1996, 94, 759-766.	2.5	10
156	Four doses of unpegylated <i>versus</i> one dose of pegylated filgrastim as supportive therapy in RÊ<scp>CHOP</scp>Ê14 for elderly patients with diffuse large BÊcell lymphoma. British Journal of Haematology, 2015, 169, 787-794.	2.5	10
157	PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells. Cancers, 2020, 12, 95.	3.7	10
158	DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica, 2006, 91, 1252-6.	3.5	10
159	Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy. OncoTargets and Therapy, 2014, 7, 1043.	2.0	9
160	Rapid response of nodular <scp>CD</scp>30Êpositive mycosis fungoides to brentuximab vedotin. British Journal of Haematology, 2015, 168, 617-617.	2.5	9
161	Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells. Blood Cancer Journal, 2020, 10, 85.	6.2	9
162	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. Scientific Reports, 2020, 10, 9156.	3.3	9

#	ARTICLE	IF	CITATIONS
163	Mutational profile of ZBTB16 ⁺ acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	2.8	9
164	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4744.	3.7	9
165	Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies. <i>Mycoses</i> , 2010, 53, 89-92.	4.0	8
166	SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011052.	1.3	8
167	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1786-1787.	1.3	8
168	A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib. <i>Chemotherapy</i> , 2021, 66, 134-138.	1.6	8
169	Progress and criticalities in the management of acute promyelocytic leukemia. <i>Oncotarget</i> , 2017, 8, 99221-99222.	1.8	8
170	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1441-1443.	1.3	7
171	Primary plasma cell leukemia followed by testicular plasmacytoma. <i>International Journal of Hematology</i> , 2011, 93, 224-227.	1.6	7
172	Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014, 93, 1413-1420.	1.8	7
173	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a Gruppo Romano Mielodisplasie (GROM) multicenter study. <i>Annals of Hematology</i> , 2016, 95, 1059-1065.	1.8	7
174	Longitudinal detection of DNMT3A ^{R882H} transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E120-E123.	4.1	7
175	Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 385-397.	2.5	7
176	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo(immuno)therapy. <i>British Journal of Haematology</i> , 2022, 198, 103-113.	2.5	7
177	Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2011, 154, 141-143.	2.5	6
178	Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far?. <i>Leukemia Research</i> , 2013, 37, 204-205.	0.8	6
179	Small lymphocytic lymphoma in a patient with Fabry disease. <i>Leukemia and Lymphoma</i> , 2013, 54, 184-185.	1.3	6
180	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacitidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	1.7	6

#	ARTICLE	IF	CITATIONS
181	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. <i>Antioxidants</i> , 2022, 11, 113.	5.1	6
182	Prevalence of obesity in young adults with acute lymphoblastic leukemia. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 117-119.	1.0	5
183	High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. <i>Annals of Hematology</i> , 2000, 79, 547-555.	1.8	5
184	5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011011.	1.3	5
185	Molecular Expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinase plasma cellular disorders: a molecular panel to investigate disease progression. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018059.	1.3	5
186	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2019, 84, 106191.	0.8	5
187	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021, 10, 128.	2.8	5
188	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	5.2	5
189	Prevalence of Mutated Factor V ARG506 to GLN in Italians. <i>Thrombosis and Haemostasis</i> , 1997, 77, 216-217.	3.4	5
190	Iron in Hodgkin's Lymphoma. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 463-469.	0.4	5
191	Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, S13-S17.	2.3	4
192	NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010021.	1.3	4
193	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	1.3	4
194	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. <i>Experimental Hematology</i> , 2014, 42, 731-733.	0.4	4
195	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. <i>Oncotarget</i> , 2017, 8, 84074-84085.	1.8	4
196	Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (<sc>MDS</sc>). <i>British Journal of Haematology</i> , 2019, 185, 954-957.	2.5	4
197	Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia. <i>Leukemia Research</i> , 2020, 99, 106462.	0.8	4
198	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2006, 108, 2479-2479.	1.4	4

#	ARTICLE	IF	CITATIONS
199	Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
200	DISAPPEARANCE OF SPONTANEOUS ERYTHROID COLONIES IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS TREATED BY ALPHA-INTERFERON. <i>British Journal of Haematology</i> , 1992, 81, 310-311.	2.5	3
201	Thrombotic thrombocytopenic purpuraâ€“hemolytic uremic syndrome after bupropion treatment for smoking cessation. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 77-78.	1.0	3
202	Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. <i>Leukemia</i> , 2004, 18, 651-653.	7.2	3
203	Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISEL trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 406-410.	1.3	3
204	Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule. <i>Leukemia Research</i> , 2012, 36, e15-e17.	0.8	3
205	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046.	1.3	3
206	Absence of FGFR3â€“TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 163-168.	0.9	3
207	Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation. <i>Cancers</i> , 2021, 13, 1083.	3.7	3
208	Blastoid Mantle Cell Lymphoma Occurring in a Patient in Complete Remission of Chronic Myelogenous Leukemia. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 30-33.	1.2	3
209	The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. <i>International Journal of Oncology</i> , 1992, , .	3.3	3
210	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. <i>Blood Advances</i> , 2022, 6, 2510-2516.	5.2	3
211	L-Asparaginase-Induced Coagulopathy in Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 7, 54-56.	1.3	2
212	Profile of azacitidine. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 717-731.	0.2	2
213	Genomic analysis of therapyâ€“related acute promyelocytic leukemias arising after malignant and nonâ€“malignant disorders. <i>American Journal of Hematology</i> , 2014, 89, 346-347.	4.1	2
214	Realâ€“life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014, 89, 565-565.	4.1	2
215	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. <i>Pharmacogenomics Journal</i> , 2018, 18, 444-449.	2.0	2
216	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. British Journal of Haematology, 2019, 186, e100-e103.	2.5	2
218	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology, 2020, 112, 141-146.	1.6	2
219	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. Acta OncolÃ³gica, 2021, 60, 1520-1526.	1.8	2
220	Mobilization and Selection of CD 34+ Cells. Recent Results in Cancer Research, 1998, , 1-7.	1.8	2
221	Polymorphism in Cytokine Genes as Prognostic Marker in Hodgkinâ€™s Lymphoma.. Blood, 2005, 106, 21-21.	1.4	2
222	Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. Blood, 1997, 89, 3763-8.	1.4	2
223	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey. Frontiers in Oncology, 2022, 12, 828072.	2.8	2
224	CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. Leukemia, 2022, , .	7.2	2
225	Hepato-Splenic Mycotic Abscesses in Patients with Acute Leukemia. Leukemia and Lymphoma, 1992, 7, 517-519.	1.3	1
226	Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 85-89.	2.8	1
227	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia and Lymphoma, 2018, 59, 1268-1270.	1.3	1
228	Could haemochromatosis (<i><sc>HFE</sc></i>) gene mutations affect response to iron chelation in myelodysplastic syndrome? â€” Response to Lucijanac and Kusec. British Journal of Haematology, 2019, 186, 639-640.	2.5	1
229	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. Leukemia and Lymphoma, 2020, 61, 979-982.	1.3	1
230	Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient. Nuclear Medicine and Molecular Imaging, 2020, 54, 256-260.	1.0	1
231	Diagnosis and Classification of AML: WHO 2016. Hematologic Malignancies, 2021, , 23-54.	0.2	1
232	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. Blood, 2020, 136, 2-2.	1.4	1
233	Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy. Blood, 2020, 136, 19-20.	1.4	1
234	Gentuzumab-Ozogamicin,Cytosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.. Blood, 2005, 106, 4604-4604.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma. Blood, 1997, 89, 3763-3768.	1.4	1
236	Profile of azacitidine. Therapy: Open Access in Clinical Medicine, 2005, 2, 717-731.	0.2	1
237	5-Azacitidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial. Blood, 2008, 112, 3648-3648.	1.4	1
238	CD34+CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. Leukemia and Lymphoma, 2021, , 1-5.	1.3	1
239	P025 Dap-kinase hypermethylation and apoptosis in myelodysplastic syndromes. Leukemia Research, 2007, 31, S54.	0.8	0
240	Reply to S. Zucker. Journal of Clinical Oncology, 2011, 29, e43-e43.	1.6	0
241	Myelodysplastic Stem Cells: Gene Expression Profiling. Stem Cells and Cancer Stem Cells, 2012, , 55-67.	0.1	0
242	An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. Blood Cancer Journal, 2015, 5, e370-e370.	6.2	0
243	Quantitation of EBV-DNA In Peripheral Blood In Hodgkin Lymphoma: Associations with Other Biomarkers and Patient Characteristics. Blood, 2010, 116, 2678-2678.	1.4	0
244	Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. Blood, 2011, 118, 2078-2078.	1.4	0
245	Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. Blood, 2012, 120, 4958-4958.	1.4	0
246	The Contact with MDS Endothelial Cells Alters the Pattern of Lineage-Specific Gene Expression During Normal Hematopoietic Differentiation. Blood, 2012, 120, 1718-1718.	1.4	0
247	Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. Blood, 2012, 120, 4951-4951.	1.4	0
248	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. Blood, 2012, 120, 3163-3163.	1.4	0
249	Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. Blood, 2013, 122, 5229-5229.	1.4	0
250	Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. Blood, 2013, 122, 5203-5203.	1.4	0
251	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. Blood, 2021, 138, 608-608.	1.4	0
252	What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?. Expert Opinion on Pharmacotherapy, 2021, , 1-6.	1.8	0

#	ARTICLE	IF	CITATIONS
253	Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation. <i>Chemotherapy</i> , 2022, 67, 24-28.	1.6	0
254	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	3.7	0